Armistice Capital’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Armistice Capital’s Portfolio SEEL Stock Details SEEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-40	Closed	-$883K	–	92
2018 Q4	$883K	Hold	40	–	–	0.07%	61
2018 Q3	$1.43M	Buy	+40	New	+$1.47M	0.09%	71
2018 Q2	–	Sell	-17	Closed	-$796K	–	92
2018 Q1	$796K	Buy	17 +10	+143%	+$1.91M	0.06%	63
2017 Q4	$1.56M	Sell	7 -6	-46%	-$1.2M	0.16%	58
2017 Q3	$2.48M	Buy	+13	New	+$2.13M	0.29%	56

Other funds holding SEEL

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Armistice Capital's SEEL Position: Q1 2019 in Review

Armistice Capital sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q1 2019, closing a stake of 40 shares — an estimated $883K sold.

Armistice Capital first reported a position in SEEL in Q3 2017 and held it in 5 quarters. The position peaked at $2.48M in Q3 2017. 10 funds tracked by Wall St. Rank hold SEEL as of Q1 2019.

Armistice Capital reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
Armistice Capital sold 40 Seelos Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $883K.
Armistice Capital first reported a position in Seelos Therapeutics, Inc. Common Stock in Q3 2017 and held it in 5 quarters.
Armistice Capital's Seelos Therapeutics, Inc. Common Stock position peaked at $2.48M in Q3 2017.
10 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Armistice Capital's 13F filing for Q1 2019, filed 15 May 2019.